<DOC>
	<DOCNO>NCT01610596</DOCNO>
	<brief_summary>This double-blind , multicenter , vehicle-controlled , parallel group comparison study determine compare efficacy safety HBP Lotion 0.05 % Vehicle Lotion apply twice daily two week subject moderate severe plaque psoriasis . Eligible subject randomize ( 1:1 ) one two treatment group - HBP Lotion 0.05 % Vehicle Lotion . The maximum amount test article apply per week exceed 50 gram .</brief_summary>
	<brief_title>A Study Determine Efficacy Safety Halobetasol Propionate Lotion 0.05 % Subjects With Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Halobetasol</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>1 . Subject Male nonpregnant female ; 18 year age time Screening . 2 . Subject willing able give write informed consent . 3. subject willing able apply test article ( ) direct , comply study instruction commit followup visit duration study . 4 . Subject clinical diagnosis stable plaque psoriasis involve minimum 2 % approximately 10 % body surface area ( BSA ) ( exclude face , scalp , groin , axillae intertriginous area ) . 5 . Subject Overall Disease Severity ( ODS ) score Treatment Area least three ( 3 ) Baseline Visit . 6 . If subject woman childbearing potential ( WOCBP ) , must negative urine pregnancy test ( UPT ) agree use effective form birth control duration study ( i.e. , abstinence , stabilize hormonal contraceptive [ oral , injectable , transdermal intravaginal ] IUD least three month prior test article application , condom spermicidal , diaphragm spermicidal ) . Abstinence acceptable form birth control subject sexually active . Subjects become sexually active trial must agree use effective form birth control duration study . 1 . Subject spontaneously improve rapidly deteriorate plaque psoriasis . 2 . Subject guttate , pustular , erythrodermic nonplaque form psoriasis . 3 . Subject physical condition , investigator 's opinion , might impair evaluation plaque psoriasis , expose subject unacceptable risk study participation . 4 . Subject use phototherapy ( include laser ) , photochemotherapy systemic corticosteroid therapy ( systemic corticosteroid [ include intralesional , intraarticular , intramuscular corticosteroid ] ) within 30 day prior Baseline Visit . 5 . Subject use systemic methotrexate , retinoids , cyclosporine analogous product within 90 day prior Baseline Visit . 6 . Subject use systemic biologic therapy ( i.e. , FDA approve experimental therapy ) within five ( 5 ) halflives biologic prior Baseline Visit . Published documented halflife product provide commercial supplier Sponsor use establish value . 7 . Subject prolonged exposure natural artificial source ultraviolet radiation within 30 day prior Baseline Visit intending exposure study think investigator likely modify subject 's disease . 8 . Subject use topical body ( exclude scalp ) psoriasis therapy include coal tar , anthralin , steroid , retinoids , vitamin D analog ( e.g. , DovonexÂ® ) within 14 day prior Baseline Visit . 9 . Subject use emollients/moisturizers area treat within four hour prior clinical evaluation Baseline Visit . 10 . Subject currently use lithium Plaquenil ( hydroxychloroquine ) . 11 . Subject currently use betablocking medication ( e.g. , propanolol ) angiotensin convert enzyme ( ACE ) inhibitor dose stabilize , opinion investigator . 12 . Subject history sensitivity ingredient test article . 13 . Subject pregnant , lactating , plan become pregnant study . 14 . Subject currently enrol investigational drug device study . 15 . Subject use investigational drug investigational device treatment within 30 day prior Baseline Visit . 16 . Subject previously enrol study treat test article . 17 . Subject know noncompliant unlikely comply requirement study protocol ( e.g. , due alcoholism , drug dependency , mental incapacity ) opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Skin Diseases</keyword>
	<keyword>Halobetasol</keyword>
	<keyword>Vasoconstrictor Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Anti-Inflammatory Agents</keyword>
	<keyword>Physiological Effects Drugs</keyword>
</DOC>